Albumin Nanoparticles as Multifunctional Carriers for Advanced Therapeutics

TL;DR

This paper explores how albumin nanoparticles can be used to deliver drugs more effectively for cancer treatment and imaging.

Contribution

The paper highlights recent advancements in albumin-based nanoparticles for theranostic applications in oncology.

Findings

Albumin-based nanoparticles like Abraxane have been successfully used in cancer treatment.

Albumin nanocarriers offer improved drug delivery and imaging capabilities.

Multimodal theranostic platforms using albumin show promise for targeted cancer therapy.

Abstract

Modern medicine requires effective, continuous, and safe therapies, which largely depend on the targeted delivery and activity of the drug. This goal can be achieved by designing drug delivery systems with improved pharmacokinetic properties and enhanced drug transport to the affected tissue. Human serum albumin (HSA) is an attractive carrier for the synthesis of therapeutic nanoparticles, several of which have already been approved by the United States Food and Drug Administration (FDA). The success of Abraxane as an effective treatment for metastatic breast cancer and non-small cell lung carcinoma, the application of Optison in ultrasound imaging, and the use of Nanocoll as an agent for SPECT diagnostics in sentinel node localisation confirm the strong potential of albumin-based systems. Further benefits are expected in patients with soft tissue cancers, as LadRx is seeking FDA marketing approval for Aldoxorubicin. The future of oncology lies in theranostics, which combines a tumour-localising factor on one platform with a drug targeting cancer cells and a factor that activates the cytotoxicity of the drug after it reaches the target tissue. This article presents recent advancements in albumin-based nanoparticles for drug delivery, targeting, and imaging. It also briefly discusses methods of synthesis and surface modification of albumin nanocarriers to enable targeted delivery to pathological sites. Finally, it outlines the latest approaches in multimodal theranostic platforms, highlighting albumin’s potential to improve cancer therapy.

Figures